DetappeLab

Pipeline

Translating drug delivery
technologies into therapeutic innovation.

Pipeline

The companies our technologies became, and how far each program has travelled.

01 / Startups

Startups.

02 / Pipeline

What left the lab.

Four nanomedicines that began in our laboratories have advanced toward or into clinical evaluation, each carried forward by a company we founded or helped build.

Stages completed Current stage Trial completed

Program

DiscoveryDisc PreclinicalPrecl Phase IPh 1 Phase IIPh 2 Phase IIIPh 3

AGuIX®

Ultrasmall gadolinium-based theranostic radioenhancer

Theraguix Co-founder, 2025–

Originated from doctoral work in the Tillement laboratory, 2013–2017

Phase II · four oncology indications · over 100 patients dosed

LEAF-4L6715

Liposomal trans-crocetin formulation correcting tissue hypoxia

Leaf4Life Shareholder, early co-PI

Co-senior corresponding author on the Phase I/II report

Phase I/II completed · COVID-19-associated ARDS

TACT

Injectable hydrogel for subcutaneous delivery of monoclonal antibodies and ADCs

Recobia Tx Co-founder and CSO, 2022–

Developed in the laboratory · four patent families on formulation, storage and release

Preclinical · lead candidate advancing toward first-in-human

ITPP adjuvant

Re-oxygenating compound counteracting tumor hypoxia

TherO2 Co-founder and board member, 2022–

Preclinical · under evaluation as an immunotherapy adjuvant

Each bar shows the most advanced stage reached by that program. Clinical development is run by the companies named; the laboratory contributes the underlying technology and the translational science behind it. The companies carrying them are listed above; the underlying IP is on the Patents page.